Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK1 Inhibitor for Large Inflammatory Hepatocellular Adenomas
NCT06490757Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2024
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in Inflammatory hepatocellular adenoma (IHCA), sponsored by Assistance publique - Hôpitaux de Paris. Started Oct 2024; status: recruiting.
02
Drugs
baricitinib
03
Conditions
Inflammatory hepatocellular adenoma (IHCA)
Beyond the preview
Go deeper on NCT06490757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490757.